Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis.
Cognitive impairment is common also in early stages of MS, but only little is known about its relationship to standard immunotherapeutic drugs. Present data suggest that both immunosuppressive as well as immunomodulatory therapy prevent or delay the onset and severity of cognitive impairment although reversible cognitive deficits can occur.
Tumani
Hayrettin
H
Neurologische Klinik, Universität Ulm, Rehabilitationskrankenhaus, Oberer Eselsberg 45, 89081, Ulm, Germany. hayrettin.tumani@uni-ulm.de
Uttner
Ingo
I
D003072:Cognition Disorders / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016899:Interferon-beta / Q000378:metabolism; D009103:Multiple Sclerosis / Q000150:complications* / Q000276:immunology
D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D016899:Interferon-beta